



#15 4/29/03 9624
RECEIVED
APR 21 2003
TECH CENTER 1600/2900

PATENT

Case 3284

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Khanna ET AL

GROUP ART UNIT: 1624

SERIAL NO.: 09/882,186

EXAMINER: K. HABTE

FILED: 15 JUNE 2001

DATE: APRIL 14, 2003

TITLE: CYCOALKYL ALKANOIC ACIDS AS INTEGRIN RECEPTOR
ANTAGONISTS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner of Patents and Trademarks
Washington, D.C. 20231
Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Rachel A. Polster

Rachel A. Polster
Attorney for Applicants
Registration No. 47,004
(314) 274-7354 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63006

**RECEIVED**

APR 21 2003

TECH. OF 2
Sheet 1 of 2
SVT 1600/253

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 3284	APPLICATION NO.: 09/882,186
	INVENTOR: Khanna, et al.	
	Filed: 6/15/01	Group: 1624

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5849736	12/15/98	Wityak et al	514	227.8	5/31/95
	2	5665754	9/9/97	Feldman et al	514	397	9/20/93
	3	5773644	6/30/98	Chen et al	562	439	3/27/97
	4	5852210	12/22/98	Chen et al	562	439	3/27/97
	5	5773646	6/30/98	Chandrakumar et al	562	439	3/27/97
	6	3654306	4/4/72	German	260	326.5	1/26/70

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	7	00/68195	11/16/00	PCT				
	8	00/33838	6/15/00	PCT				
	9	94/27947	12/8/94	PCT				
	10	0747346	5/31/96	EP				
	11	97/19049	5/29/97	PCT				
	12	95/03288	2/2/95	PCT				

Duplicate

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



RECEIVED

APR 21 2003

TECH CENTER 400
(Form PTO-1449)
Sheet 2 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 3284	APPLICATION NO.: 09/882,186
	INVENTOR: Khanna, et al.	
	Filed: 6/15/01	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	13	Miller, et al, <i>J. Med. Chem.</i> , 43, 22-26, 2000
	14	Wityak et al, <i>J. Med. Chem.</i> , 40, 50-60, 1997

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)